A multicenter, Randomized, Double-Blind, Placebo-Controlled clinical study of HuoXin Wan (concentrated pill) for the treatment of stable angina pectoris with the syndrome of qi deficiency and blood stasis
DUAN Wen-hui
XU Hao
WANG Cui-ping
GAO Hong-chun
LI Yun-lun
CHEN Yu-shan
PENG Guang-cao
GUAN Huai-min
Abstract：Objective To evaluate the efficacy and safety of HuoXin Wan (concentrated pill) for the treatment of stable angina pectoris.Methods A multicenter, randomized, double-blind, placebo-controlled clinical trial was carried out in 131 patients with the syndrome of qi deficiency and blood stasis. Patients were randomly divided into two groups: test group received Huoxin wan (concentrated pill), and the control group received placebo. After 8-weeks’treatment, 48 patients of them received electrocardiogram treadmill exercise test (total exercise time, time of ST segment decreased 0.1mV or occurrence of angina pectoris, maximum extent of ST segment reduction, number of leads of ST-segment depressed than 0.1mV, Metabolic equivalents), and the efficacy and safety of HuoXin Wan (concentrated pill) were evaluated, including symptom score of angina pectoris, the reduce amount of nitroglycerin, SAQ score, change of TCM syndrome, inflammatory factors and blood fat.Results After 8-weeks treatment, Symptom score of angina pectoris in test group was significantly lower than control group (P<0.01). Seattle Angina Questionnaire (SAQ) and the reduce amount of Nitroglycerin in test group was significantly lower than control group (P<0.01), Curative efficacy of TCM in test group was better than control group (P<0.01). The number of leads of ST-segment depressed than 0.1mV of test group was reduced significantly than that of control group (P<0.01). Maximum extents of ST segment reduction in leads V4, V5 and V6 were lower than control group (P<0.05). There was no significant difference between the two groups as to inflammatory factors, blood fat and the incidence of adverse events (P>0.05).Conclusion HuoXin Wan (concentrated pill) is effective and safe for the treatment of stable angina pectoris in patients with the syndrome of qi deficiency and blood stasis.
Keywords：Coronary heart diseaseStable angina pectorisQi deficiency and blood stasisHuoXin WanClinical trial
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1110-1115 )